Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.

Australia became the first country to allow authorized prescribing of MDMA for PTSD outside clinical trials. Interviews with 21 clinicians, researchers, and patients who had direct experience with MDMA-assisted psychotherapy or PTSD revealed eleven themes, including the importance of expectation management, comprehensive baseline screening, shared decision-making, flexible treatment protocols, ongoing consent, strong therapeutic alliance, and post-treatment continuity of care. The findings emphasize the need for safeguards, provider training, and integration of care as MDMA-assisted psychotherapy enters clinical practice.

Study at a glance

Abstract

Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic stress disorder (PTSD) outside of clinical trials. This study explored the direct experience of Australian clinicians, researchers, and patients regarding the use of MDMA-assisted psychotherapy (MDMA-AP) for PTSD to inform guideline development. In-depth semi-structured interviews were conducted with clinicians, researchers, and patients who had direct experience with the use of MDMA-AP or PTSD. Interviews were transcribed verbatim and coded. Themes were developed using both inductive and deductive approaches (guided by the World Health Organization Guide to Good Prescribing framework). Twenty-one interviews were conducted with clinicians (mental health-focused general practitioners, psychiatrists, psychologists, therapists), researchers (health economist, pharmacologist, social worker, trial researcher), and patients. Eleven themes emerged: (1) role of MDMA-AP in relation to established PTSD therapies; (2) importance of expectation management and shared decision-making; (3) perceived therapeutic benefits of MDMA-AP; (4) importance of comprehensive baseline screening (medical, psychological, financial, and social support); (5) variable patient values and preferences; (6) desire for flexible treatment protocols; (7) importance of comprehensive and ongoing consent; (8) duty of care in establishing strong therapeutic alliance; (9) patient need for information about process and logistics; (10) treatment monitoring and discontinuation; and (11) importance of post-treatment continuity of care. Australians with direct experience of the use of MDMA-AP or PTSD highlight the importance of expectation management, comprehensive screening, consent, safeguard measures, therapeutic alliance, integration of care, and training of healthcare providers. As MDMA-AP becomes implemented into clinical practice, there is scope to incorporate these insights into a national guideline.